.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AX05_Fondaparinux.Fondaparinux .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AX05_Fondaparinux.Fondaparinux| name: | Fondaparinux |
| ATC code: | B01AX05 | route: | subcutaneous |
| n-compartments | 1 |
Fondaparinux is a synthetic pentasaccharide anticoagulant that selectively inhibits Factor Xa via antithrombin III. It is used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after orthopedic surgery. Fondaparinux is approved and currently used in clinical practice.
Pharmacokinetic parameters in healthy adult volunteers after subcutaneous administration.
Hanada, K, et al., & Takahashi, H (2018). Population pharmacokinetics and pharmacodynamics of fondaparinux in Japanese patients after artificial total knee replacement . International journal of clinical pharmacology and therapeutics 56(6) 255–262. DOI:10.5414/CP203169 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29595122
Bauer, KA, et al., & Meuleman, DG (2002). Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovascular drug reviews 20(1) 37–52. DOI:10.1111/j.1527-3466.2002.tb00081.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/12070533
Gerotziafas, GT, et al., & Elalamy, I (2014). New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Therapeutics and clinical risk management 10 423–436. DOI:10.2147/TCRM.S49063 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24966680